1-5 of 5
Frank G. Haluska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1268–1276.
https://doi.org/10.1158/1078-0432.CCR-21-2037
Published: 01 April 2022
View article titled, Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Open the PDF for Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers in another window
Includes: Supplementary data
Journal Articles

A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors

Lia Gore, Tanya M. Trippett, Howard M. Katzenstein, Jessica Boklan, Aru Narendran, Amy Smith, Margaret E. Macy, Katherine Rolla, for the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narayana Narashimhan, Rachel M. Squillace, Christopher D. Turner, Frank G. Haluska, Michael Nieder
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3649–3658.
https://doi.org/10.1158/1078-0432.CCR-12-3166
Published: 30 June 2013
View article titled, A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors
Open the PDF for A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors in another window
Journal Articles

Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference

Michael B. Atkins, David E. Elder, Richard Essner, Keith T. Flaherty, Thomas F. Gajewski, Frank G. Haluska, Patrick Hwu, Ulrich Keilholz, John M. Kirkwood, James W. Mier, Merrick I. Ross, Craig L. Slingluff, Vernon K. Sondak, Jeffrey A. Sosman, Martin A. Weinstock, Laura King
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2291s–2296s.
https://doi.org/10.1158/1078-0432.CCR-05-2560
Published: 11 April 2006
View article titled, Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference
Open the PDF for Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference in another window
Journal Articles

Genetic Alterations in Signaling Pathways in Melanoma

Frank G. Haluska, Hensin Tsao, Helen Wu, Frank S. Haluska, Alexander Lazar, Vikas Goel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2301s–2307s.
https://doi.org/10.1158/1078-0432.CCR-05-2518
Published: 11 April 2006
View article titled, Genetic Alterations in Signaling Pathways in Melanoma
Open the PDF for Genetic Alterations in Signaling Pathways in Melanoma in another window
Journal Articles

Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

Gerald P. Linette, Dongsheng Zhang, F. Stephen Hodi, Eric P. Jonasch, Simonne Longerich, Christopher P. Stowell, Iain J. Webb, Heather Daley, Robert J. Soiffer, Amy M. Cheung, Sara G. Eapen, Sharon V. Fee, Krista M. Rubin, Arthur J. Sober, Frank G. Haluska
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7692–7699.
https://doi.org/10.1158/1078-0432.CCR-05-1198
Published: 08 November 2005
View article titled, Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8<sup>+</sup> Immunity
Open the PDF for Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8<sup>+</sup> Immunity in another window